A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Drug Category : Array
Conference Category : Array
Lead Author : Barr P, et al.
Published Date : 08/12/2019
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/12/ASH2019PBarrU2V.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top